Pfizer Q2 Revenue Rises 10% to $14.7 Billion, Raises Full-Year EPS Guidance to $2.90–$3.10

Pfizer Inc. (NYSE: PFE) delivered strong financial results for the second quarter of 2025, surpassing market expectations with improved performance across multiple therapeutic areas and a raised full-year earnings per share (EPS) guidance [1]. The company reported Q2 revenue of $14.7 billion, representing a 10% year-over-year increase. This growth was driven by robust demand for key products including Vyndaqel, Comirnaty, and Paxlovid, supported by favorable foreign exchange impacts [1].

The adjusted diluted EPS for the quarter was $0.78, significantly outpacing the expected $0.573 and reflecting a 30% increase from the same period in 2024 [2]. Meanwhile, the reported diluted EPS stood at $0.51, a substantial improvement from last year’s $0.01 [1]. This performance highlights Pfizer’s ability to manage operational challenges and leverage a diversified product portfolio to drive profitability.

In light of these results, the company has raised its full-year 2025 adjusted EPS guidance to a range of $2.90 to $3.10, an upward revision of $0.10 from the previous forecast of $2.80 to $3.00 [3]. The updated guidance factors in ongoing cost-improvement initiatives, favorable tax rate adjustments, and continued operational efficiencies. Although revenue guidance for the year remains unchanged at $61.0 billion to $64.0 billion [1], the improved EPS outlook signals confidence in the company’s strategic execution and momentum in key therapeutic areas.

Pfizer’s GAAP earnings for Q2 2025 totaled $2.91 billion, or $0.51 per share, compared to $41 million, or $0.01 per share, in the same period in 2024 [1]. This represents a dramatic year-over-year improvement, underscoring the company’s financial resilience and operational strength. Following the earnings announcement, Pfizer’s stock rose by 3.27%, reflecting investor optimism about the company’s performance and revised guidance [4].

The results are in line with Pfizer’s long-term growth strategy, which emphasizes innovation, portfolio diversification, and operational efficiency. Analysts have noted that the company’s strategic focus on cost savings, estimated at $7.2 billion by the end of 2027, is a key driver of its margin expansion and long-term value creation [2]. As the company continues to advance its research and development pipeline, it remains well-positioned to deliver sustained growth and meet its full-year objectives.

Pfizer’s strong Q2 performance and raised EPS guidance demonstrate its ability to navigate a challenging market environment and maintain a competitive edge in the pharmaceutical sector. With ongoing momentum in its key therapeutic areas and a disciplined approach to cost management, the company appears poised for continued success in the remainder of 2025.

Source: [1]Pfizer Inc. Q2 Profit Rises (https://www.rttnews.com/3561962/pfizer-inc-q2-profit-rises.aspx?type=ern)

[2]Pfizer (PFE) tops Q2 results, raises FY2025 EPS outlook (https://www.msn.com/en-us/money/topstocks/earnings-snapshot-pfizer-pfe-tops-q2-results-raises-fy2025-eps-outlook/ar-AA1JWjb6?ocid=finance-verthp-feeds)

[3]Pfizer Boost Adj. EPS FY25 Outlook - Update (https://www.rttnews.com/3561990/pfizer-boost-adj-eps-fy25-outlook-update.aspx?type=ern)

[4]Pfizer (PFE) Soars 3.27% on 10% Revenue Jump (https://www.ainvest.com/news/pfizer-pfe-soars-3-27-10-revenue-jump-2508/)